Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder

NCT04155424 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04155424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients With Relapsing Neuromyelitis Optica Spectrum Disorder
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
January 14, 2020
Completion date
July 31, 2023
Enrollment
5 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica, neuromyelitis optica spectrum disorder